Free Trial

Century Therapeutics (IPSC) Competitors

$2.86
+0.17 (+6.32%)
(As of 04:32 PM ET)

IPSC vs. NKTX, IVVD, KNTE, FATE, BLUE, RLAY, DNA, MESO, PRME, and HLVX

Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Nkarta (NKTX), Invivyd (IVVD), Kinnate Biopharma (KNTE), Fate Therapeutics (FATE), bluebird bio (BLUE), Relay Therapeutics (RLAY), Ginkgo Bioworks (DNA), Mesoblast (MESO), Prime Medicine (PRME), and HilleVax (HLVX). These companies are all part of the "medical" sector.

Century Therapeutics vs.

Century Therapeutics (NASDAQ:IPSC) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Nkarta has lower revenue, but higher earnings than Century Therapeutics. Nkarta is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century Therapeutics$2.23M102.91-$136.67M-$2.21-1.25
NkartaN/AN/A-$117.50M-$2.35-2.26

Nkarta received 18 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 72.73% of users gave Nkarta an outperform vote while only 62.50% of users gave Century Therapeutics an outperform vote.

CompanyUnderperformOutperform
Century TherapeuticsOutperform Votes
30
62.50%
Underperform Votes
18
37.50%
NkartaOutperform Votes
48
72.73%
Underperform Votes
18
27.27%

Century Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

In the previous week, Century Therapeutics had 3 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Century Therapeutics and 0 mentions for Nkarta. Nkarta's average media sentiment score of 1.84 beat Century Therapeutics' score of 0.53 indicating that Nkarta is being referred to more favorably in the news media.

Company Overall Sentiment
Century Therapeutics Positive
Nkarta Very Positive

Century Therapeutics currently has a consensus target price of $13.80, indicating a potential upside of 400.00%. Nkarta has a consensus target price of $17.83, indicating a potential upside of 238.39%. Given Century Therapeutics' higher probable upside, research analysts clearly believe Century Therapeutics is more favorable than Nkarta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Nkarta
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Nkarta has a net margin of 0.00% compared to Century Therapeutics' net margin of -9,742.41%. Nkarta's return on equity of -34.13% beat Century Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics-9,742.41% -59.74% -32.51%
Nkarta N/A -34.13%-25.96%

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 6.8% of Century Therapeutics shares are held by company insiders. Comparatively, 8.7% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nkarta beats Century Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPSC vs. The Competition

MetricCentury TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$229.49M$2.87B$5.15B$8.44B
Dividend YieldN/A2.30%2.82%4.09%
P/E Ratio-1.2512.77137.3915.37
Price / Sales102.91284.952,199.1666.63
Price / CashN/A146.1532.9430.92
Price / Book0.913.644.714.17
Net Income-$136.67M-$45.13M$110.01M$216.16M
7 Day Performance-11.50%-5.49%-2.41%-1.28%
1 Month Performance-6.73%-11.01%-4.98%-4.30%
1 Year Performance-21.08%-9.21%-4.03%-0.08%

Century Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTX
Nkarta
2.1349 of 5 stars
$5.67
-5.7%
$17.83
+214.5%
+8.7%$280.19MN/A-2.41150Positive News
IVVD
Invivyd
2.5507 of 5 stars
$1.47
-7.0%
$11.33
+671.0%
+11.0%$175.40MN/A-0.7994
KNTE
Kinnate Biopharma
3.04 of 5 stars
$2.65
-0.4%
$8.15
+207.5%
-17.2%$125.13MN/A-0.9584High Trading Volume
FATE
Fate Therapeutics
4.4293 of 5 stars
$3.57
-1.1%
$6.75
+89.1%
-38.8%$406.37M$63.53M-1.86181Gap Up
BLUE
bluebird bio
2.3848 of 5 stars
$0.95
-1.0%
$5.46
+473.7%
-75.7%$104.11M$3.60M-1.29323Positive News
RLAY
Relay Therapeutics
2.0384 of 5 stars
$7.09
-3.0%
$22.80
+221.6%
-43.5%$970.34M$35.33M-2.69323Positive News
DNA
Ginkgo Bioworks
2.4275 of 5 stars
$0.43
-4.5%
$1.90
+343.0%
-78.4%$948.42M$251.46M-0.971,218
MESO
Mesoblast
2.1197 of 5 stars
$7.24
-0.5%
$13.67
+88.8%
-16.4%$826.66M$7.50M-6.4683Analyst Forecast
News Coverage
Positive News
PRME
Prime Medicine
3.4851 of 5 stars
$6.35
-10.7%
$15.09
+137.7%
-59.5%$762.19MN/A-2.93234
HLVX
HilleVax
2.4275 of 5 stars
$15.29
+1.3%
$29.00
+89.7%
-23.1%$760.22MN/A-4.6390

Related Companies and Tools

This page (NASDAQ:IPSC) was last updated on 6/21/2024 by MarketBeat.com Staff

From Our Partners